Novo Nordisk
Research Novo Nordisk (NVO) on Bullrun: valuation model: 62.6% undervalued, market cap USD 129.28B, P/E 9.4, dividend yield 4.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNVO
- ExchangeNYSE
- CountryDenmark
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal62.6% undervalued
- Market capUSD 129.28B
- P/E9.4
- Dividend yield4.8%
- Financial periodQ2 2026
- RevenueDKK 78.49B
- Net incomeDKK 20.99B
- Free cash flowDKK 42.40B
- Gross margin78.2%
Valuation Snapshot
Bullrun's latest valuation model marks Novo Nordisk as 62.6% undervalued; latest market cap is USD 129.28B; P/E is 9.4; dividend yield is 4.8%.
Peer valuation comparison
Latest P/E is 9.44x versus a Healthcare sector median of 24.61x (61.6% below).
Latest dividend yield is 4.81% versus a Healthcare sector median of 1.84% (161.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 309.06B | DKK 102.43B | DKK 28.99B | 81.0% | 23.03 | DKK 26.46B | DKK 130.96B | DKK 194.05B |
| FY2024 | DKK 290.40B | DKK 100.99B | DKK 69.66B | 84.7% | 22.63 | DKK 15.66B | DKK 102.79B | DKK 143.49B |
| FY2023 | DKK 232.26B | DKK 83.68B | DKK 70.01B | 84.6% | 18.62 | DKK 14.39B | DKK 27.01B | DKK 106.56B |
| FY2022 | DKK 176.95B | DKK 55.53B | DKK 64.13B | 83.9% | 12.22 | DKK 12.65B | DKK 25.78B | DKK 83.49B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 129.28B | 9.4 | 4.8% | 1.85 |
| 2025 | 2025-12-31 | USD 226.08B | 14.7 | 2.2% | 1.1 |
| 2024 | 2024-12-31 | USD 382.04B | 26.2 | 1.7% | 1.44 |
| 2023 | 2023-12-29 | USD 461.21B | 42.9 | 1.0% | 1.03 |
| 2022 | 2022-12-30 | USD 304.50B | 40.3 | 1.2% | 0.81 |
| 2021 | 2021-12-31 | USD 258.72B | 33.9 | 1.3% | 0.75 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.85 USD, yield 4.8%.
| Year | Dividends/share |
|---|---|
| FY2025 | 1.1 DKK |
| FY2024 | 1.44 DKK |
| FY2023 | 1.03 DKK |
| FY2022 | 0.81 DKK |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Novo Nordisk overvalued or undervalued?
Bullrun's valuation model currently marks Novo Nordisk as 62.6% undervalued.
What is Novo Nordisk's market cap?
Novo Nordisk's market capitalization is USD 129.28B.
What is Novo Nordisk's P/E ratio?
Novo Nordisk's price-to-earnings (P/E) ratio is 9.4.
Does Novo Nordisk pay a dividend?
Novo Nordisk has a dividend yield of 4.8%.
What does Novo Nordisk do?
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.